Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Moss, A. Kirk, M. McKean, C. O‘Brien, D. Spencer (Newcastle upon Tyne, United Kingdom). The use of omalizumab in the management of severe chronic paediatric asthma. Eur Respir J 2008; 32: Suppl. 52, 3062

Member's Comments

No comment yet.

Related content which might interest you: Cost implications for the introduction of omalizumab in to the management of severe chronic asthma in children Source: Eur Respir J 2006; 28: Suppl. 50, 481s Year: 2006 Combination asthma medication and healthcare use in severe or difficult-to-treat asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 Acute severe asthma: evidence-based management of asthma exacerbations Source: Annual Congress 2008 - PG4 - Paediatric respiratory medicine: wheezing children: asthma and beyond Year: 2008 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 The management of mild asthma Source: Eur Respir J, 57 (4) 2003051; 10.1183/13993003.03051-2020 Year: 2021 The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe chronic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Management of difficult-to-treat severe asthma Source: Eur Respir Mon 2011; 51: 282-296 Year: 2011 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Omalizumab decreases medical resource utilisation in patients with severe allergic asthma in an Italian real-life setting Source: International Congress 2017 – Asthma management Year: 2017 Biologic therapies in paediatric severe asthma Source: ERS webinar 2020: Biologic therapies in paediatric severe asthma Year: 2020 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 The Anglo-French real-life experience of maintenance OCS use in omalizumab-treated patients with severe persistent allergic asthma Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Pharmacological strategies for self-management of asthma exacerbations Source: Eur Respir J 2006; 28: 182-199 Year: 2006 Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Evaluation of the difficult-to-treat severe asthma patient in the clinic Source: Eur Respir Mon 2011; 51: 16-27 Year: 2011 An economic evaluation of adding inhaled corticosteroids to systemic corticosteroids for treating acute asthma exacerbations Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019 Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Antibiotics use for asthma exacerbation in Japanese geriatric patients Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies Year: 2019